✦ LIBER ✦

Blood leukocyte subsets and cytokine profile after autologous peripheral blood stem cell transplantation

✍ Scribed by S.W. Krause; G. Rothe; M. Gnad; A. Reichle; R. Andreesen

Publisher: Springer
Year: 2003
Tongue: English
Weight: 263 KB
Volume: 82
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-003-0716-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cytomegalovirus enteritis after autologo

Cytomegalovirus enteritis after autologous peripheral blood stem cell transplantation

✍ T. Kozuka; K. Takenaka; K. Shinagawa; K. Masuda; T. Ishihara; Y. Arimori; S. Fuk 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 37 KB

Cerebral Toxoplasmosis After Autologous

Cerebral Toxoplasmosis After Autologous Peripheral Blood Stem Cell Transplantation

✍ M. López-Duarte; A. Insunza; E. Conde; A. Iriondo; F. Mazorra; A. Zubizarreta 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 118 KB

Exfoliative Esophagitis Early After Auto

Exfoliative Esophagitis Early After Autologous Peripheral Blood Stem Cell Transplantation

✍ Satoshi Hashino; Koji Chiba; Nobuyasu Toyoshima; Sachiko Suzuki; Mitsutoshi Kuro 📂 Article 📅 2001 🏛 Carden Jennings Publishing 🌐 English ⚖ 148 KB

Changes of immunological markers after a

Changes of immunological markers after autologous peripheral blood stem cell transplantation

✍ Kaoruko Katsura; Shosaku Nomura; Tetsuji Ohtani; Noriaki Matsumoto; Toshiki Shim 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 190 KB

Cellular and humoral immune reconstituti

Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT)

✍ P. Reimer; V. Kunzmann; M. Wilhelm; B. Weißbrich; D. Kraemer; H. Berghammer; F. 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 181 KB

Autologous peripheral blood progenitor c

Autologous peripheral blood progenitor cell transplantation

✍ Kenneth C. Anderson 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 871 KB

Harvesting of autologous peripheral blood stem cells (PBSCs) has been facilitated by using currently available, efficient apheresis technology at the time of rebound from chemotherapy while patients are receiving recombinant growth factors, i.e., granulocyte (G) or granulocyte-macrophage (GM) colony